Koyal Jain

Koyal Jain

Auto-generated profile, based on publicly available information

Koyal Jain

Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Advances in Chronic Kidney Disease
Verified
Journal Article
Closed access
EKElizabeth S. Kotzen
Elizabeth S. Kotzen
SRSanjeet Roy
Sanjeet Roy
KJKoyal Jain
Koyal Jain

8 April 2023 in Medical Clinics of North America
Verified
Journal Article
Closed access
MRMaria Jose Zabala Ramirez
Maria Jose Zabala Ramirez
ESEva J. Stein
Eva J. Stein
KJKoyal Jain
Koyal Jain

29 April 2021 in Kidney360
Verified
Journal Article
Closed access
PDF file
KJKoyal Jain
Koyal Jain
PJPankaj Jawa
Pankaj Jawa
VDVimal K. Derebail
Vimal K. Derebail
RFRonald J. Falk
Ronald J. Falk
ANCA vasculitis is a small-vessel vasculitis (SVV) resulting in inflammation of small- and medium-sized blood vessels. Since the initial description of SVV, there have been tremendous advances in our understanding of its pathogenesis. Over the last decade, we have made significant progress in understanding the pathogenesis and improving the treatment and prognosis of patients with ANCA vasculitis. Patient and renal survival has improved, and treatment is moving toward individualizing care, minimizing severe adverse events, and preventing relapse. This review focuses on treatment updates in ANCA vasculitis, duration of therapy, and management of relapses. We also describe the existing treatment protocols used at our institution.

1 June 2022 in Lupus
Verified
Journal Article
Open access
DMDavid Massicotte-Azarniouch
David Massicotte-Azarniouch
EKElizabeth Kotzen
Elizabeth Kotzen
STSarah Todd
Sarah Todd
YHYichun Hu
Yichun Hu
SHSusan L. Hogan
Susan L. Hogan
KJKoyal Jain
Koyal Jain
Introduction: Lupus nephritis (LN) may present with thrombotic microangiopathy (TMA) on kidney biopsy, the impact of which on outcomes is unclear. This study examined the prognostic importance of LN with TMA on kidney biopsy, including response to therapy and long-term outcomes. Methods: We conducted a single-center, retrospective study of all cases of LN with concomitant TMA on kidney biopsy in the Glomerular Disease Collaborative Network database. Controls were individuals with LN without TMA matched to cases based on demographic and clinical variables. Outcomes were remission at 6- and 12-months, end-stage kidney disease (ESKD) and death. Logistic regression and Cox proportional hazards models were used to ascertain the risks for outcomes, with adjustment for serum creatinine and proteinuria. Results: There were 17 cases and 28 controls. Cases had higher creatinine, higher proteinuria and greater chronicity on biopsy at baseline compared to controls. The rates of remission at 6-months and 12-months were similar between cases and controls (6-months 53.9% vs 46.4%, adjusted OR 2.54, 95% CI 0.48, 13.37; 12-months 53.9% vs 50.0%, adjusted OR 2.95, 95% CI 0.44, 19.78). Cases were at greater risk for ESKD in univariate analysis (HR 3.77; 95% CI 1.24, 11.41) but not when adjusting for serum creatinine and proteinuria (HR 2.20; 95% CI 0.63, 7.71). There was no significant difference in the risk of death between cases and controls. Conclusion: Lupus nephritis with renal TMA likely responds to therapy similarly to those without TMA; risk for ESKD is not significantly increased, although the influence of renal function and proteinuria in larger samples is needed.

20 November 2024 in Advances in Kidney Disease and Health
Verified
Journal Article
Closed access
AKAbbal Koirala
Abbal Koirala
PSPurva D. Sharma
Purva D. Sharma
KJKenar Dinesh Jhaveri
Kenar Dinesh Jhaveri
KJKoyal Jain
Koyal Jain
DGDuvuru Geetha
Duvuru Geetha

7 May 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
NWNicole E. Wyatt
Nicole E. Wyatt
VDVimal K. Derebail
Vimal K. Derebail
RFRonald J. Falk
Ronald J. Falk
KJKoyal Jain
Koyal Jain
ANCA-associated vasculitis (AAV) is a rare and potentially fatal autoimmune disorder characterized by pauci-immune necrotizing vasculitis affecting small- to medium-sized blood vessels. The pathogenic role of ANCAs in AAV is supported by both clinical and experimental evidence, and when used in the proper clinical setting, ANCA testing is highly specific for AAV. Testing with both indirect immunofluorescence assay and enzyme immunoassay may increase sensitivity for AAV; however, testing with a high-quality enzyme immunoassay may be used alone. Nonvasculitic conditions and drugs can cause ANCA positivity without manifestations of AAV. We review ANCA testing itself, performance characteristics and specific conditions for the laboratory test, and various conditions when ANCA testing is useful in diagnosis, disease monitoring, and selecting treatment.